As of 2026-10-13, the EV/EBITDA ratio of Vanda Pharmaceuticals Inc (VNDA) is -1.40. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. VNDA's latest enterprise value is 226.14 mil USD. VNDA's TTM EBITDA according to its financial statements is -161.10 mil USD. Dividing these 2 quantities gives us the above VNDA EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 10.1x - 15.0x | 10.8x |
| Forward P/E multiples | 9.1x - 17.6x | 14.9x |
| Fair Price | (26.19) - (39.48) | (33.61) |
| Upside | -673.1% - -963.9% | -835.5% |
| Date | EV/EBITDA |
| 2026-10-09 | -1.40 |
| 2026-10-08 | -1.39 |
| 2026-10-07 | -1.40 |
| 2026-10-06 | -1.39 |
| 2026-10-05 | -1.41 |
| 2026-10-02 | -1.43 |
| 2026-10-01 | -1.49 |
| 2026-09-30 | -1.53 |
| 2026-09-29 | -1.58 |
| 2026-09-28 | -1.63 |
| 2026-09-25 | -1.58 |
| 2026-09-24 | -1.56 |
| 2026-09-23 | -1.58 |
| 2026-09-22 | -1.64 |
| 2026-09-21 | -1.62 |
| 2026-09-18 | -1.61 |
| 2026-09-17 | -1.61 |
| 2026-09-16 | -1.56 |
| 2026-09-15 | -1.56 |
| 2026-09-14 | -1.62 |
| 2026-09-11 | -1.60 |
| 2026-09-10 | -1.58 |
| 2026-09-09 | -1.66 |
| 2026-09-08 | -1.69 |
| 2026-09-04 | -1.72 |
| 2026-09-03 | -1.69 |
| 2026-09-02 | -1.76 |
| 2026-09-01 | -1.72 |
| 2026-08-31 | -1.71 |
| 2026-08-28 | -1.67 |
| 2026-08-27 | -1.73 |
| 2026-08-26 | -1.69 |
| 2026-08-25 | -1.73 |
| 2026-08-24 | -1.69 |
| 2026-08-21 | -1.67 |
| 2026-08-20 | -1.71 |
| 2026-08-19 | -1.78 |
| 2026-08-18 | -1.73 |
| 2026-08-17 | -1.66 |
| 2026-08-14 | -1.65 |
| 2026-08-13 | -1.58 |
| 2026-08-12 | -1.64 |
| 2026-08-11 | -1.54 |
| 2026-08-10 | -1.57 |
| 2026-08-07 | -1.56 |
| 2026-08-06 | -1.61 |
| 2026-08-05 | -1.60 |
| 2026-08-04 | -1.69 |
| 2026-08-03 | -1.65 |
| 2026-07-31 | -1.60 |